Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2011 1
2012 1
2014 2
2015 4
2016 3
2017 1
2018 4
2019 2
2020 2
2021 5
2022 2
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia.
Grob T, Sanders MA, Vonk CM, Kavelaars FG, Rijken M, Hanekamp DW, Gradowska PL, Cloos J, Fløisand Y, van Marwijk Kooy M, Manz MG, Ossenkoppele GJ, Tick LW, Havelange V, Löwenberg B, Jongen-Lavrencic M, Valk PJM. Grob T, et al. Among authors: kavelaars fg. J Clin Oncol. 2023 Feb 1;41(4):756-765. doi: 10.1200/JCO.22.00715. Epub 2022 Oct 31. J Clin Oncol. 2023. PMID: 36315929 Free PMC article.
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome.
Grob T, Al Hinai ASA, Sanders MA, Kavelaars FG, Rijken M, Gradowska PL, Biemond BJ, Breems DA, Maertens J, van Marwijk Kooy M, Pabst T, de Weerdt O, Ossenkoppele GJ, van de Loosdrecht AA, Huls GA, Cornelissen JJ, Beverloo HB, Löwenberg B, Jongen-Lavrencic M, Valk PJM. Grob T, et al. Among authors: kavelaars fg. Blood. 2022 Apr 14;139(15):2347-2354. doi: 10.1182/blood.2021014472. Blood. 2022. PMID: 35108372 Free PMC article.
Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Al Hinai A, Zeilemaker A, Erpelinck-Verschueren CAJ, Gradowska PL, Meijer R, Cloos J, Biemond BJ, Graux C, van Marwijk Kooy M, Manz MG, Pabst T, Passweg JR, Havelange V, Ossenkoppele GJ, Sanders MA, Schuurhuis GJ, Löwenberg B, Valk PJM. Jongen-Lavrencic M, et al. Among authors: kavelaars fg. N Engl J Med. 2018 Mar 29;378(13):1189-1199. doi: 10.1056/NEJMoa1716863. N Engl J Med. 2018. PMID: 29601269 Free article.
Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL.
Hengeveld PJ, van der Klift MY, Kolijn PM, Davi F, Kavelaars FG, de Jonge E, Robrecht S, Assmann JLJC, van der Straten L, Ritgen M, Westerweel PE, Fischer K, Goede V, Hallek M, Levin MD, Langerak AW. Hengeveld PJ, et al. Among authors: kavelaars fg. Blood. 2023 Feb 2;141(5):519-528. doi: 10.1182/blood.2022017411. Blood. 2023. PMID: 36084320 Free article.
Recurrently affected genes in juvenile myelomonocytic leukaemia.
Obenauer JC, Kavelaars FG, Sanders MA, de Vries ACH, de Haas V, Beverloo HB, De Moerloose B, Lammens T, Dworzak M, Hoogenboezem RM, Valk PJM, Touw IP, van den Heuvel-Eibrink MM. Obenauer JC, et al. Among authors: kavelaars fg. Br J Haematol. 2018 Jul;182(1):135-138. doi: 10.1111/bjh.14737. Epub 2017 May 9. Br J Haematol. 2018. PMID: 28485469 Free article. No abstract available.
RUNX1 germline variants in RUNX1-mutant AML: how frequent?
Ernst MPT, Kavelaars FG, Löwenberg B, Valk PJM, Raaijmakers MHGP. Ernst MPT, et al. Among authors: kavelaars fg. Blood. 2021 Mar 11;137(10):1428-1431. doi: 10.1182/blood.2020008478. Blood. 2021. PMID: 33075818 Free article. No abstract available.
Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia.
Hengeveld PJ, Schilperoord-Vermeulen J, van der Klift MY, Dubois JMN, Kolijn PM, Kavelaars FG, Rijken M, Dobber JA, Nasserinejad K, Kersting S, Westerweel PE, Kater AP, Langerak AW, Levin MD. Hengeveld PJ, et al. Among authors: kavelaars fg. Blood Cancer J. 2023 Jul 4;13(1):102. doi: 10.1038/s41408-023-00870-2. Blood Cancer J. 2023. PMID: 37400508 Free PMC article. No abstract available.
Protein functionality as a potential bottleneck for somatic revertant variants.
Kaiser FMP, Reisli I, Pico-Knijnenburg I, Langerak AW, Kavelaars FG, Artac H, IJspeert H, van der Burg M. Kaiser FMP, et al. Among authors: kavelaars fg. J Allergy Clin Immunol. 2021 Jan;147(1):391-393.e8. doi: 10.1016/j.jaci.2020.04.045. Epub 2020 May 15. J Allergy Clin Immunol. 2021. PMID: 32422145 Free article. No abstract available.
Selective Requirement of MYB for Oncogenic Hyperactivation of a Translocated Enhancer in Leukemia.
Smeenk L, Ottema S, Mulet-Lazaro R, Ebert A, Havermans M, Varea AA, Fellner M, Pastoors D, van Herk S, Erpelinck-Verschueren C, Grob T, Hoogenboezem RM, Kavelaars FG, Matson DR, Bresnick EH, Bindels EM, Kentsis A, Zuber J, Delwel R. Smeenk L, et al. Among authors: kavelaars fg. Cancer Discov. 2021 Nov;11(11):2868-2883. doi: 10.1158/2159-8290.CD-20-1793. Epub 2021 May 12. Cancer Discov. 2021. PMID: 33980539 Free PMC article.
DNA vs cDNA FLT3-ITD allelic ratio and length measurements in adult acute myeloid leukemia.
Cucchi DGJ, Vonk CM, Rijken M, Kavelaars FG, Merle PA, Verhoef E, Venniker-Punt B, Kwidama ZJ, Gradowska P, Löwenberg B, Janssen JJWM, Cloos J, Valk PJM. Cucchi DGJ, et al. Among authors: kavelaars fg. Blood Adv. 2021 Nov 9;5(21):4476-4479. doi: 10.1182/bloodadvances.2021004980. Blood Adv. 2021. PMID: 34525176 Free PMC article. No abstract available.
26 results